Income Statement
ALLARITY THERAPEUTICS, INC.
ALLR
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - |
|
Operating Expenses
|
12.93 | 27.24 | 17.13 | 34.46 | 26.56 |
|
Research & Development
|
6.60 | 6.10 | 7.10 | 6.93 | 14.20 |
|
Selling, General & Administrative
|
6.32 | 11.44 | 10.03 | 9.96 | 12.36 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-12.93 | -27.24 | -17.13 | -34.46 | -26.56 |
|
Non-Operating Income
|
1.37 | 2.35 | 5.31 | 16.88 | - |
|
Interest Income
|
0.80 | 0.53 | 0.02 | 0.03 | - |
|
Interest Expense
|
0.20 | 0.20 | 2.69 | 0.11 | 0.10 |
|
Other Non-Op Income / Expense
|
- | - | - | - | 0.04 |
|
Income Before Tax
|
-11.23 | -24.90 | -5.58 | - | - |
|
Income Tax Expense
|
0.00 | -0.38 | 0.08 | -1.52 | 0.13 |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-11.23 | -24.52 | 35.79 | -16.06 | -26.65 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-12.93 | -27.23 | -17.09 | -34.40 | -26.45 |
|
Earnings Per Share (Basic)
|
-0.78 | -15.65 | -10.26 | -2.21 | -4.19 |
|
Diluted EPS
|
- | - | -10.26 | -2.21 | - |
|
Weighted Average Shares
|
14.38 | 1.61 | 1.99 | 9.53 | 6.36 |
|
Diluted Weighted Avg Shares
|
- | - | 1.99 | 9.53 | 6.36 |
|
Comprehensive Income
|
-11.90 | -24.46 | -11.59 | -16.18 | -28.62 |